WeForNews | Latest News, Breaking News, News Updates Rafale controversy: France, Dassault Aviation denies involvement in choosing Indian partners | WeForNews | Latest News, Blogs
Connect with us

India

Rafale controversy: France, Dassault Aviation denies involvement in choosing Indian partners

Published

on

Rafale deal scam

New Delhi, Sep 22 : The French government and Dassault Aviation have denied their involvement in the choice of Indian industrial partners in the multi-million dollar Rafale jet deal.

The statement by the French government issued here late Friday comes after former President Francois Hollande’s reported claim that the Indian government suggested a particular private firm for Rafale offset contract.

Hollande was quoted in an article by a French website as claiming that the Indian government had asked the French government to nominate Reliance Defence as its India partner in the deal.

“We did not have a say in this,” Hollande was quoted by the website as saying. “The Indian government proposed this service group and Dassault negotiated with Ambani.”

In response to the claim, the Friday night statement said: “The French government is in no manner involved in the choice of Indian industrial partners who have been, are being or will be selected by French companies.

“In accordance with India’s acquisition procedure, French companies have the full freedom to choose their Indian partner companies that they consider to be the most relevant, then present for the Indian government’s approval the offset projects that they wish to execute in India with these local partners so as to fulfil their obligations in this regard.”

Dassault Aviation, the makers of the Rafale jets, in a statement also on Friday night, said: “This offsets contract is delivered in compliance with the Defence Procurement Procedure (DPP) 2016 regulations. In this framework, and in accordance with the policy of ‘Make in India’, Dassault Aviation has decided to make a partnership with India’s Reliance Group. This is Dassault Aviation’s choice.”

The Paris-based company said that the partnership between the two giants led to the creation of the “Dassault Reliance Aerospace Ltd (DRAL) joint-venture in February 2017.

“Dassault aviation is very proud that the Indian authoritie have selected the Rafale fighter,” it added.

The deal to purchase 36 Rafale fighter jets from France was announced by Prime Minister Narendra Modi in 2015 and signed in 2016.

The UPA government was earlier negotiating a deal to procure 126 Rafale jets, with 18 to come in flyaway condition and 108 to be manufactured by HAL under licence.

The Modi government has repeatedly said it was Dassault that chose its India partner for offsets and that the government had no say in the deal.

Cities

Delhi reports 51 cases of minor adverse events post vaccination

As many as 1,91,181 people were vaccinated on day one of India’s first phase of the coronavirus vaccination drive.

Published

on

By

Covid 19 Vaccine

Hours after the Health Ministry announced on January 16 that India has reported no case of post-vaccination hospitalisation yet, 51 persons complained of minor adverse events in Delhi. Another person developed severe adverse event following immunization and had to be referred to the AEFI centre.

Out of a total of 4,319 healthcare and frontline workers who were vaccinated on Jnauary 16 in the National Capital, two healthcare workers at NDMC’s Charak Palika Hospital reported mild adverse event post-vaccination including mild tightness in the chest. They were kept under observation by AEFI team and discharged 30 minutes later after they felt at ease. The two other cases were reported from Northern Railway Central Hospital, of which one was referred to the AEFI centre, the Delhi government has informed.

As many as 1,91,181 people were vaccinated on day one of India’s first phase of the coronavirus vaccination drive.

Beneficiaries from 11 states and union territories across India received Covishield or Covaxin shots on the first day of the vaccination drive, namely, Assam, Bihar, Delhi, Haryana, Karnataka, Maharashtra, Odisha, Rajasthan, Tamil Nadu, Telangana, and Uttar Pradesh.

Follow our coverage of the coronavirus crisis here

Continue Reading

Health

Bharat Biotech to pay compensation if Covaxin causes side-effects

The vaccine maker said in phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19

Published

on

By

COVAXIN Corona Covid vaccine

Hyderabad, January 16: Bharat Biotech, which has received a government purchase order for supply of 55 lakh doses of Covaxin, a COVID-19 vaccine, said the company would pay compensation to recipients in case of any serious adverse effects experienced after receiving the antidote.

In the consent form to be signed by the vaccine recipients, Bharat Biotech said: “In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres/hospitals.”

“The compensation for serious adverse event will be paid by sponsor (BBIL) in case if the SAE is proven to be causally related to the vaccine,” the consent form said.

In phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antidotes against COVID- 19. However, the clinical efficacy of the vaccine was yet to be established and it was still being studied in phase 3 clinical trials, the vaccine maker said.

“Hence it is important to appreciate that receiving the vaccine does not mean that other precautions related to COVID-19 need not be followed,” the consent form said.

According to an industry expert, the company is liable to pay compensation to people in case of serious side effects as the vaccine is being administered while in the clinical trial mode.

The central licensing authority has granted permission for the sale or distribution of Covaxin for restricted use in emergency situations in public interest as an abundant caution, in clinical trial mode.

Meanwhile, Suchitra Ella, joint managing director, Bharat Biotech International Limited, on her Twitter account said: “Covaxin & Bharat Biotech is truly humbled & honoured to be of service to the nation & the fraternity of all first responders of covid who have served public health.” — PTI

Continue Reading

Cities

AIIMS security guard reports allergy post COVID vaccination, in hospital care

Delhi has reported 52 adverse events following events of which one is serious and could involve the guard hospitalised today.

Published

on

By

Vaccine

New Delhi, January 16

A 22-year-old security guard at AIIMS, New Delhi reported allergic reaction and is learnt to be in intensive care, moments after the government said there was no post-vaccine hospitalisation.

The 22-year-old guard developed headache, rash, respiratory distress, tachycardia after vaccination. He is in ICU and his condition is stable, hospital sources said.

Delhi has reported 52 adverse events following events of which one is serious and could involve the guard hospitalised today.

All beneficiaries vaccinated at AIIMS got indigenous COVAXIN.

Continue Reading
Advertisement

Most Popular